Compare AbbVie Inc (ABBV) vs Western Digital Corp (WDC) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

WDC trades at $434.3, down 3.81% over 24 hours, with a bearish technical signal as it hovers near the pivot point of $440. The company has shown strong earnings beats in recent quarters, with Q2 2026 EPS of $3.56 surpassing the $3.31 estimate, and maintains robust profitability margins, including a net income margin of 72.95% for 2025. Revenue for 2025 was $9.52B, with a significant turnaround to net income of $1.86B from prior losses, indicating operational recovery amid high cloud demand.

The outlook is mixed, with analyst consensus strongly bullish (72.13% buy ratings) and a price target of $665.15 suggesting substantial upside, but risks include high valuation multiples like a P/E of 17.89 and EV/EBITDA of 29.99, competitive pressures in HDD storage, and recent post-earnings sell-offs due to margin concerns. Investors should weigh the growth potential from AI-driven storage demand against cyclical and valuation headwinds.